PE20211280A1 - Sales cristalinas de un inhibidor de calicreina plasmatica - Google Patents
Sales cristalinas de un inhibidor de calicreina plasmaticaInfo
- Publication number
- PE20211280A1 PE20211280A1 PE2021000587A PE2021000587A PE20211280A1 PE 20211280 A1 PE20211280 A1 PE 20211280A1 PE 2021000587 A PE2021000587 A PE 2021000587A PE 2021000587 A PE2021000587 A PE 2021000587A PE 20211280 A1 PE20211280 A1 PE 20211280A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hydrogen
- plasmatic
- crystalline salts
- delivery system
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000011230 binding agent Substances 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000023178 Musculoskeletal disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 abstract 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Referido a un sistema de administracion de farmacos que comprende D-R, que esta representado por la Formula (I), donde D es un resto biologicamente activo que comprende al menos una amina primaria o secundaria o un atomo de nitrogeno anular de un anillo de azaheteroarilo; y R es un ligante adecuado para la liberacion del resto biologicamente activo D; R1 es hidrogeno o C1-C4 alquilo; R1a es hidrogeno o C1-C4 alquilo, entre otros; R2 se selecciona independientemente entre C1-C4 alquilo o oxo, entre otros; a es 0, 1, 2, 3 o 4; R3 es hidrogeno o C1-C4 alquilo; R3a es hidrogeno, C1-C4 alquilo, entre otros; Y es C(O)R4, C(O)OR4, entre otros; y Z es CH-L-A, CH-A, N-L-A o N-A, donde L es un enlazador bivalente opcionalmente sustituido; A es hidrogeno, C1-C8 alquilo, entre otros. Tambien se refiere a un portador que se conjuga al farmaco a traves del ligante estable. Dicho sistema de administracion es util para el tratamiento de trastornos musculoesqueleticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754983P | 2018-11-02 | 2018-11-02 | |
| PCT/US2019/059385 WO2020092898A1 (en) | 2018-11-02 | 2019-11-01 | Crystalline salts of a plasma kallikrein inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211280A1 true PE20211280A1 (es) | 2021-07-19 |
Family
ID=70457981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000587A PE20211280A1 (es) | 2018-11-02 | 2019-11-01 | Sales cristalinas de un inhibidor de calicreina plasmatica |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10662160B1 (es) |
| EP (1) | EP3873463A4 (es) |
| JP (1) | JP2022505670A (es) |
| KR (1) | KR20210087037A (es) |
| CN (1) | CN112969458A (es) |
| AR (1) | AR116951A1 (es) |
| AU (1) | AU2019374115A1 (es) |
| BR (1) | BR112021008249A2 (es) |
| CA (1) | CA3117123A1 (es) |
| CL (1) | CL2021001094A1 (es) |
| CO (1) | CO2021007172A2 (es) |
| EA (1) | EA202191192A1 (es) |
| IL (1) | IL282454A (es) |
| MA (1) | MA54087A (es) |
| MX (1) | MX2021004917A (es) |
| PE (1) | PE20211280A1 (es) |
| PH (1) | PH12021550883A1 (es) |
| SG (1) | SG11202103804TA (es) |
| TW (1) | TW202031255A (es) |
| UY (1) | UY38438A (es) |
| WO (1) | WO2020092898A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016020199A8 (pt) | 2014-03-07 | 2021-07-20 | Biocryst Pharm Inc | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| WO2021025969A1 (en) * | 2019-08-02 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of berotralstat |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) * | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| AU2011254658B2 (en) | 2010-05-19 | 2016-02-18 | Sandoz Ag | Purification of posaconazole and of posaconazole intermediates |
| GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| BR112016020199A8 (pt) | 2014-03-07 | 2021-07-20 | Biocryst Pharm Inc | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
-
2019
- 2019-10-31 UY UY0001038438A patent/UY38438A/es unknown
- 2019-10-31 AR ARP190103187A patent/AR116951A1/es unknown
- 2019-11-01 CN CN201980072995.3A patent/CN112969458A/zh active Pending
- 2019-11-01 US US16/671,649 patent/US10662160B1/en active Active
- 2019-11-01 SG SG11202103804TA patent/SG11202103804TA/en unknown
- 2019-11-01 PE PE2021000587A patent/PE20211280A1/es unknown
- 2019-11-01 EA EA202191192A patent/EA202191192A1/ru unknown
- 2019-11-01 MA MA054087A patent/MA54087A/fr unknown
- 2019-11-01 BR BR112021008249-2A patent/BR112021008249A2/pt unknown
- 2019-11-01 EP EP19877809.4A patent/EP3873463A4/en active Pending
- 2019-11-01 CA CA3117123A patent/CA3117123A1/en active Pending
- 2019-11-01 JP JP2021522086A patent/JP2022505670A/ja active Pending
- 2019-11-01 MX MX2021004917A patent/MX2021004917A/es unknown
- 2019-11-01 AU AU2019374115A patent/AU2019374115A1/en active Pending
- 2019-11-01 WO PCT/US2019/059385 patent/WO2020092898A1/en unknown
- 2019-11-01 KR KR1020217013734A patent/KR20210087037A/ko active Search and Examination
- 2019-11-01 TW TW108139655A patent/TW202031255A/zh unknown
-
2020
- 2020-02-06 US US16/784,016 patent/US11117867B2/en active Active
-
2021
- 2021-04-20 IL IL282454A patent/IL282454A/en unknown
- 2021-04-21 PH PH12021550883A patent/PH12021550883A1/en unknown
- 2021-04-27 CL CL2021001094A patent/CL2021001094A1/es unknown
- 2021-05-31 CO CONC2021/0007172A patent/CO2021007172A2/es unknown
- 2021-09-02 US US17/465,181 patent/US11618733B2/en active Active
-
2023
- 2023-03-10 US US18/120,073 patent/US20240109844A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022505670A (ja) | 2022-01-14 |
| MX2021004917A (es) | 2021-06-18 |
| IL282454A (en) | 2021-06-30 |
| US20200140389A1 (en) | 2020-05-07 |
| US11618733B2 (en) | 2023-04-04 |
| EP3873463A4 (en) | 2022-06-22 |
| US10662160B1 (en) | 2020-05-26 |
| KR20210087037A (ko) | 2021-07-09 |
| PH12021550883A1 (en) | 2022-02-21 |
| EP3873463A1 (en) | 2021-09-08 |
| EA202191192A1 (ru) | 2021-09-23 |
| MA54087A (fr) | 2022-02-09 |
| AU2019374115A1 (en) | 2021-06-03 |
| BR112021008249A2 (pt) | 2021-08-03 |
| US20240109844A1 (en) | 2024-04-04 |
| CO2021007172A2 (es) | 2021-06-10 |
| WO2020092898A1 (en) | 2020-05-07 |
| US20220204454A1 (en) | 2022-06-30 |
| US11117867B2 (en) | 2021-09-14 |
| AR116951A1 (es) | 2021-06-30 |
| CA3117123A1 (en) | 2020-05-07 |
| CL2021001094A1 (es) | 2021-10-15 |
| TW202031255A (zh) | 2020-09-01 |
| UY38438A (es) | 2020-05-29 |
| US20200308118A1 (en) | 2020-10-01 |
| SG11202103804TA (en) | 2021-05-28 |
| CN112969458A (zh) | 2021-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191837A1 (es) | Sistema de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas | |
| PE20211280A1 (es) | Sales cristalinas de un inhibidor de calicreina plasmatica | |
| SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| HN2012001037A (es) | Derivados del acido carbamoil-metil-amino-acetico sustiituido como inhibidores de nep novedosos | |
| AR049647A1 (es) | Cis-imidazolinas | |
| ECSP11011560A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| CO6270307A2 (es) | Derivados bis-(sulfonilamino) en terapia | |
| UY31468A1 (es) | Derivados bis-(sulfonilamino) en terapia 065 | |
| AR061419A1 (es) | Compuestos de piridil amida sustituidos como moduladores del receptor de histamida h3 | |
| PE20211646A1 (es) | Administracion sostenida de polipeptidos similares a la angiopoyetina 3 | |
| AR051315A1 (es) | Pirimidinas 5-sustituidas inhibidoras del vih | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CL2019000768A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
| CY1111102T1 (el) | 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv | |
| PE20190106A1 (es) | Inhibidores del potenciador del homologo zeste 2 | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| CL2023000418A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| CL2019000727A1 (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos. | |
| CL2020001277A1 (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. | |
| PE20040943A1 (es) | 2-AMINOIMIDAZOLES SUSTITUIDOS COMO INHIBIDORES DEL INTERCAMBIADOR Na/H SUBTIPO 3 (NHE 3) | |
| DOP2023000205A (es) | Nuevos moduladores de nr2b alostéricos negativos de ciclopenta[c]pirrol | |
| AR085822A1 (es) | Moduladores alostericos positivos del receptor nicotinico de acetilcolina | |
| UY39722A (es) | Nuevos derivados de heteroaril aminopropanol | |
| CU20160170A7 (es) | Derivados de carboxamida |